Therapeutic Advances In Vaccines And Immunotherapy impact factor, indexing, ranking (2024)

Aim and Scope

The Therapeutic Advances In Vaccines And Immunotherapy is a research journal that publishes research related to Immunology and Microbiology; Medicine; Pharmacology, Toxicology and Pharmaceutics. This journal is published by the SAGE Publications Ltd. The ISSN of this journal is 25151355, 25151363. Based on the Scopus data, the SCImago Journal Rank (SJR) of therapeutic advances in vaccines and immunotherapy is 0.8.

Also, please check the following important details about therapeutic advances in vaccines and immunotherapy: Publisher, ISSN, Ranking, Indexing, Impact Factor (if applicable), Publication fee (APC), Review Time, and Acceptance Rate.

According to Clarivate's JCR, journals indexed in SCIE/SSCI have an impact factor.

Therapeutic Advances In Vaccines And Immunotherapy Ranking

Journal Rank: 5982

SJR (SCImago Journal Rank): 0.8

Quartile: Q2

H-Index: 10

The SJR (SCImago Journal Rank) measures citations weighted by prestige. It is useful for comparing journals within the same field, and forms the basis of the subject category ranking. A journal SJR indicator is a numeric value representing the average number of weighted citations received during a selected year per document published in that journal during the previous three years, as indexed by Scopus. Higher SJR indicator values are meant to indicate greater journal prestige. SJR is developed by the Scimago Lab, originated from a research group at University of Granada. Q1 journals are cited more often and by more prestigious journals than those in the other quartiles.

Each subject category of journals is divided into four quartiles: Q1, Q2, Q3, Q4. Q1 is occupied by the top 25% of journals in the list; Q2 is occupied by journals in the 25 to 50% group; Q3 is occupied by journals in the 50 to 75% group and Q4 is occupied by journals in the 75 to 100% group.

CiteScore of an academic journal is a measure reflecting the yearly average number of citations to recent articles published in that journal. This journal evaluation metric was launched in December 2016 by Elsevier as an alternative to the generally used JCR impact factors (calculated by Clarivate). CiteScore is based on the citations recorded in the Scopus database rather than in JCR, and those citations are collected for articles published in the preceding four years instead of two or five.

Source Normalized Impact per Paper (SNIP) is calculated annually from Scopus data. It is a sophisticated metric that intrinsically accounts for field-specific differences in citation practices.

Important Metrics

Journal Title:	Therapeutic Advances in Vaccines and Immunotherapy
Publisher:	SAGE Publications Ltd
ISSN:	25151355, 25151363
Type:	journal
Journal Scope:	Immunology and Microbiology; Medicine; Pharmacology, Toxicology and Pharmaceutics
Country:	United Kingdom
H-Index:	10
SJR:	0.8
Quartile:	Drug Discovery (Q2); Immunology and Allergy (Q2); Oncology (Q2); Pharmacology (medical) (Q2); Immunology (Q3)

therapeutic advances in vaccines and immunotherapy Indexing

The therapeutic advances in vaccines and immunotherapy is indexed in:

UGC CARE
Scopus
DOAJ
PubMed

An indexed journal means that the journal has gone through and passed a review process of certain requirements done by a journal indexer.

The Web of Science Core Collection includes the Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts & Humanities Citation Index (AHCI), and Emerging Sources Citation Index (ESCI).

Therapeutic Advances In Vaccines And Immunotherapy Quartile

The latest Quartile of therapeutic advances in vaccines and immunotherapy is Q2.

Publication fee

Based on the Official Journal Homepage, the therapeutic advances in vaccines and immunotherapy does not charge any publication fee.

An article processing charge (APC), also known as a publication fee, is a fee which is sometimes charged to authors. Most commonly, it is involved in making a work available as open access (OA), in either a full OA journal or in a hybrid journal.

Call for Papers

Visit to the official website of the journal/ conference to check the details about call for papers.

How to publish in Therapeutic Advances In Vaccines And Immunotherapy?

If your research is related to Immunology and Microbiology; Medicine; Pharmacology, Toxicology and Pharmaceutics, then visit the official website of therapeutic advances in vaccines and immunotherapy and send your manuscript.

Tips for publishing in Therapeutic Advances In Vaccines And Immunotherapy:

Selection of research problem.
Presenting a solution.
Designing the paper.
Make your manuscript publication worthy.
Write an effective results section.
Mind your references.

Acceptance Rate

Acceptance rate is the ratio of the number of articles submitted to the number of articles published. Researchers can check the acceptance rate on the journal website. Alternatively, they can contact the editor of the journal.

Journal Publication Time

The Journal Publication Time means the average number of weeks between article submission and publication. According to the journal website, the therapeutic advances in vaccines and immunotherapy publishes research articles in 8 weeks on an average.

Final Summary

It is published by SAGE Publications Ltd.
The journal is indexed in UGC CARE, Scopus, DOAJ, PubMed.
It is an open access journal.
The (SJR) SCImago Journal Rank is 0.8.
The publication time (Average number of weeks between article submission and publication) of the journal is 8 weeks.
Based on the Official Journal Homepage, the therapeutic advances in vaccines and immunotherapy does not charge any publication fee.